<DOC>
	<DOCNO>NCT00477282</DOCNO>
	<brief_summary>The objective study assess safety efficacy karenitecin versus topotecan patient platinum/taxane-resistant advanced epithelial ovarian cancer . Additionally , study assess ability karenitecin extend time disease progression , extend overall survival time , reduce incidence severity treatment related hematological toxicity patient advance epithelial ovarian cancer .</brief_summary>
	<brief_title>Karenitecin Versus Topotecan Patients With Advanced Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Age ≥ 18 year Confirmed diagnosis stage III IV epithelial ovarian cancer Have cancer resistant platinum/taxanebased chemotherapy regimen Have measurable , progressive disease Have ECOG PS ≤ 2 Have uncontrolled high blood pressure , uncontrolled diabetes mellitus , serious underlie medical condition compatible study entry . Have life expectancy &lt; 3 month Received prior treatment camptothecin ( topotecan , CPT11 , investigational camptothecins ) . Received prior treatment platinum agent cisplatin carboplatin . Received prior radiation therapy great onethird hematopoietic site ( onethird pelvis axial skeleton combine ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced Ovarian Cancer</keyword>
</DOC>